Markman M
Semin Oncol. 1985 Sep;12(3 Suppl 4):33-7.
At the UCSD Cancer Center several chemotherapeutic agents have been evaluated for safety and clinical utility when delivered by the intraperitoneal route. Both melphalan and cytarabine have demonstrated a major pharmacokinetic advantage for peritoneal cavity exposure to drug compared to that of the plasma when these agents are administered directly into the abdominal cavity. In addition, limited clinical efficacy for both agents has been demonstrated. In one experimental system cisplatin and cytarabine have shown significant concentration-dependent synergy. As intraperitoneal drug delivery allows one to administer extremely high concentrations of chemotherapeutic agents to tumors localized to the abdominal cavity, this therapeutic approach is perhaps the optimal method for producing clinically relevant concentration-dependent drug synergy. Patients with refractory ovarian carcinoma and other tumors principally confined to the peritoneal cavity have demonstrated subjective and objective improvement following intraperitoneal therapy with a cisplatin-cytarabine-based chemotherapeutic regimen.
在加州大学圣地亚哥分校癌症中心，已对多种化疗药物通过腹腔内途径给药时的安全性和临床效用进行了评估。当美法仑和阿糖胞苷直接注入腹腔时，与血浆相比，它们在腹腔暴露于药物方面显示出主要的药代动力学优势。此外，这两种药物都已显示出有限的临床疗效。在一个实验系统中，顺铂和阿糖胞苷已显示出显著的浓度依赖性协同作用。由于腹腔内给药可使人们将极高浓度的化疗药物施用于局限于腹腔的肿瘤，这种治疗方法可能是产生临床相关浓度依赖性药物协同作用的最佳方法。难治性卵巢癌和其他主要局限于腹腔的肿瘤患者，在接受基于顺铂 - 阿糖胞苷的化疗方案进行腹腔内治疗后，已表现出主观和客观上的改善。
